1490 on Drugs and Therapeutics Safety of Testosterone Replacement Therapy ...p 33 Zarxio – A Filgrastim Biosimilar ...p 34 Low-Dose Meloxicam Vivlodex for Osteoarthritis Pain ...p 35 I
Trang 1FORWARDING OR COPYING IS A VIOLATION OF U.S AND INTERNATIONAL COPYRIGHT LAWS
The Medical Letter, Inc publications are protected by U.S and international copyright laws Forwarding, copying or any distribution of this material is prohibited.
Sharing a password with a non-subscriber or otherwise making the contents of this site available to third parties is strictly prohibited.
By accessing and reading the attached content I agree to comply with U.S and international copyright laws and these terms and conditions of The Medical Letter, Inc.
For further information click: Subscriptions, Site Licenses, Reprints
or call customer service at: 800-211-2769
Important Copyright Message
IN THIS ISSUE
ISSUE
1433
Volume 56
Published by The Medical Letter, Inc • A Nonprofi t Organization
ISSUE No
1490
on Drugs and Therapeutics
Safety of Testosterone Replacement Therapy p 33
Zarxio – A Filgrastim Biosimilar p 34
Low-Dose Meloxicam (Vivlodex) for Osteoarthritis Pain p 35
Isavuconazonium Sulfate (Cresemba) – A New Antifungal Drug p 37
Trang 2
33
on Drugs and Therapeutics
ISSUE
1433
Volume 56
ISSUE No
1490 Zarxio – A Filgrastim Biosimilar Low-Dose Meloxicam (Vivlodex) for Osteoarthritis Pain p 34 p 35
Isavuconazonium Sulfate (Cresemba) – A New Antifungal p 37
ALSO IN THIS ISSUE
Safety of Testosterone Replacement
Therapy
▶
Three coordinated double-blind, placebo-controlled
clinical trialshave evaluated the effi cacy of one year of
testosterone replacement therapy in improving sexual
function, physical function, and vitality in a total of
790 men ≥65 years old with moderately low serum
testosterone concentrations and symptoms
suggest-ing hypoandrogenism Sexual function improved
modestly, and there appeared to be marginal benefi ts
in some areas of physical function and vitality as well
The trials were not designed to evaluate the safety of testosterone replacement therapy.1
ADVERSE EFFECTS — Testosterone administration
has been associated with development of acne, gynecomastia, peripheral edema, and polycythemia Injections of testosterone undecanoate rarely have caused pulmonary oil microembolism (POME) and anaphylactic reactions The main concern with testosterone replacement therapy, however, has been the possibility that it could increase the risk of prostate cancer and cardiovascular disease
For further information call: 800-211-2769
Table 1 Some Testosterone Replacement Products
Drug Some Available Formulations Usual Adult Dosage Cost 1
Injectable
Testosterone cypionate – generic 1, 10 mL vial (100 mg/mL, 200 mg/mL) 2,7 50-400 mg IM $45.30
Testosterone enanthate – generic 5 mL vial (200 mg/mL) 7 50-400 mg IM 68.00
Testosterone undecanoate – Aveed 3 mL vial (250 mg/mL) 750 mg IM at 0 and 850.00
Transdermal
Testosterone 1% gel packet – 2.5 g gel packet (25 mg test.); 5 g gel packet (50 mg test.); 50 mg once/d
(40.5 mg test.); 75 g MDP (20.25 mg test in 1.25 g gel/act)
Testosterone 2% gel – generic 60 g MDP (10 mg test in 0.5 g gel/act) 40 mg once/d 341.30
Testosterone 1% gel – generic 5 g tube of gel (50 mg test.); 5 g gel packet (50 mg test.) 5 ; 50 mg once/d 309.60
Vogelxo (Upsher Smith) 88 g MDP (12.5 mg test in 1.25 g gel/act) 445.50
Intranasal
Buccal
act = actuation; MDP = metered-dose pump; test = testosterone
1 Approximate wholesale acquisition cost (WAC) for one 10-mL vial (100 mg/mL) of testosterone cypionate, one 5-mL vial of testosterone enanthate, one 3-mL
vial of Aveed, or a 30-day supply of transdermal, intranasal, or buccal formulations at the usual adult dosage WAC = wholesaler acquisition cost or
manu-facturer’s published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price Source: AnalySource® Monthly February 5, 2016 Reprinted with permission by First Databank, Inc All rights reserved ©2016 www.fdbhealth.com/policies/drug-pricing-policy Cost of administration is not included.
2 The 100 mg/mL formulation is only available in a 10-mL vial.
3 AndroGel 1%, the reference product for these formulations, is no longer manufactured.
4 Should be administered as 1 pump actuation (30 mg) to each axilla.
5 Tubes and packets are therapeutically equivalent to Testim.
6 Should be administered as 1 pump actuation (5.5 mg) in each nostril.
7 Vial should be discarded within 28 days after being opened or accessed (United States Pharmacopeia General Chapter 797).
Trang 3
The Medical Letter ® Vol 58 (1490) March 14, 2016
5 L Xu et al Testosterone therapy and cardiovascular events among men: a systematic review and meta-analysis of place-bo-controlled randomized trials BMC Med 2013; 11:108.
6 G Corona et al Cardiovascular risk associated with testos-terone-boosting medications: a systematic review and meta-analysis Expert Opin Drug Saf 2014; 13:1327.
7 R Sharma et al Normalization of testosterone level is associ-ated with reduced incidence of myocardial infarction and mor-tality in men Eur Heart J 2015; 36:2706.
8 A Morgentaler et al Testosterone therapy and cardiovascu-lar risk: advances and controversies Mayo Clin Proc 2015; 90:224.
Prostate Cancer – Testosterone replacement
therapy has been associated with increases in serum
prostate-specifi c antigen (PSA) concentrations
In the coordinated trials, which excluded men at
high risk for prostate cancer, a PSA increase of
≥1.0 ng/mL occurred in 23 men treated with
testosterone and 8 treated with placebo Four men
developed prostate cancer during the trials or in
the subsequent year; three were in the testosterone
group Large randomized controlled trials are
lack-ing, but recent reviews have found no convincing
evidence that higher testosterone levels increase the
risk of prostate cancer.2,3
Cardiovascular Disease – Some studies have found
an association between testosterone replacement
therapy and cardiovascular events In the coordinated
trials, 7 men in each treatment group had a major
cardiovascular event
In an earlier 6-month randomized trial in 209 men ≥65
years old with a high prevalence of cardiac risk factors,
23 treated with testosterone gel had
cardiovascular-related adverse events, compared to 5 who received
placebo (HR 2.4; p=0.05).4 A meta-analysis of
ran-domized, placebo-controlled trials also found an
increased risk of cardiovascular-related adverse
events in men treated with testosterone (OR 1.54;
95% CI 1.09-2.18); an analysis by funding source
found that the risk was greater in trials not sponsored
by the pharmaceutical industry (OR 2.06 vs 0.89).5
Other studies have not found an association between
testosterone replacement therapy and cardiovascular
risk, and some have found a reduced incidence of
myocardial infarction and mortality in men treated
with testosterone.6-8
CONCLUSION — The safety of testosterone
replace-ment therapy remains unclear There is no convincing
evidence to date that it increases the risk of prostate
cancer Some studies have found an increased
incidence of cardiovascular events in men treated with
testosterone, but others have not ■
1 PJ Snyder et al Effects of testosterone treatment in older men
N Engl J Med 2016; 374:611.
2 JE Michaud et al Testosterone and prostate cancer: an
evi-dence-based review of pathogenesis and oncologic risk Ther
Adv Urol 2015; 7:378.
3 P Boyle et al Endogenous and exogenous testosterone and the
risk of prostate cancer and increased prostate specifi c antigen
(PSA): a meta-analysis BJU Int 2016 January 18 (epub).
4 S Basaria et al Adverse events associated with testosterone
administration N Engl J Med 2010; 363:109.
Zarxio – A Filgrastim Biosimilar
▶
The FDA has approved fi lgrastim-sndz (Zarxio –
Sandoz), a biosimilar of the recombinant human granulocyte colony-stimulating factor fi lgrastim
(G-CSF; Neupogen), which has been available in the
US since 1991 Zarxio is the fi rst biosimilar product to
be approved in the US; it has been available in Europe
as Zarzio since 2009.
Pronunciation Key Filgrastim : fi l gra' stim Zarxio : zar' zee oh
BIOSIMILARS — The FDA defi nes a biosimilar as a
biologic product that is highly similar to an approved biologic product (reference product) with no clinically meaningful differences in safety, purity, or potency; minor differences in clinically inactive components are allowed An approved biosimilar product must have the same mechanism of action, route of administration, dosage form, and strength as the reference product Biosimilars can only be approved for the indications for which the reference product is approved; they may be approved for fewer indications than the reference product A biosimilar that is approved as
an “interchangeable product” (see Table 1) can be substituted by a pharmacist for the reference product.1
Table 1 FDA Criteria for Interchangeability of Biosimilars
▶ The biosimilar product can be expected to produce the same clinical result as the reference product in any given patient.
▶ If the biosimilar product is administered more than once to an individual, the risk in terms of safety or diminished effi cacy of alternating or switching between use of the biosimilar product and the reference product is not greater than the risk of using the reference product without such alternation or switch.
Zarxio was approved for all of the same indications
as the US-licensed reference product Neupogen (see
Table 2), but was not reviewed for interchangeability
CLINICAL STUDIES — In a phase 1, randomized,
double-blind, two-way crossover trial in 28 healthy subjects, no statistically signifi cant pharmacokinetic
Trang 4or pharmacodynamic differences were detected
between 10 mcg/kg doses of fi lgrastim-sndz and
Neupogen The safety profi les of the two products
were also similar.2
In a double-blind noninferiority trial, 218 women
with breast cancer who were being treated with
myelosuppressive chemotherapy were randomized
to receive 5 mcg/kg/day of subcutaneous Zarxio
or Neupogen, or an alternating course of the two
drugs over six chemotherapy cycles Doses were
administered from day 2 of each cycle until the
abso-lute neutrophil count recovered or for a maximum of
14 days The mean duration of severe neutropenia in
cycle 1, the primary endpoint, was similar with Zarxio
and Neupogen Alternating between the two products
produced no clinically meaningful differences in
effi cacy or safety.3
Table 2 Approved Indications for Neupogen and Zarxio
▶ Decrease the incidence of infection‚ as manifested by febrile
neutropenia‚ in patients with nonmyeloid malignancies receiving
myelosuppressive anticancer drugs associated with a signifi cant
incidence of severe neutropenia with fever
▶ Reduce the time to neutrophil recovery and the duration of fever,
following induction or consolidation chemotherapy treatment of
patients with acute myeloid leukemia
▶ Reduce the duration of neutropenia and
neutropenia-related clinical sequelae‚ e.g.‚ febrile neutropenia, in patients
with nonmyeloid malignancies undergoing myeloablative
chemotherapy followed by bone marrow transplantation
▶ Mobilize autologous hematopoietic progenitor cells into the
peripheral blood for collection by leukapheresis
▶ Reduce the incidence and duration of sequelae of severe
neutropenia (e.g.‚ fever‚ infections‚ oropharyngeal ulcers) in
symptomatic patients with congenital neutropenia‚ cyclic
neutropenia‚ or idiopathic neutropenia
Table 3 Neupogen and Zarxio
Drug Available Formulations Cost 1
Filgrastim – 300 mcg/0.5 mL, 480 mcg/0.8 mL
Neupogen (Amgen) prefi lled syringe; 300 mcg/1 mL, $516.45
480 mcg/1.6 mL vial
Filgrastim-sndz – 300 mcg/0.5 mL, 480 mcg/0.8 mL
Zarxio (Sandoz) prefi lled syringe 438.98
1 Approximate WAC for one 480 mcg/0.8 mL prefi lled syringe WAC =
whole-saler acquisition cost or manufacturer’s published price to wholewhole-salers;
WAC represents a published catalogue or list price and may not represent
an actual transactional price Source: AnalySource® Monthly February 5,
2016 Reprinted with permission by First Databank, Inc All rights reserved
©2016 www.fdbhealth.com/policies/drug-pricing-policy.
ADVERSE EFFECTS — In clinical trials, there were no
signifi cant differences in adverse effects between
Zarxio and Neupogen The most common dose-
and cycle-related adverse effects of fi lgrastim have
been pyrexia, pain (including bone and chest pain),
rash, thrombocytopenia, nausea, fatigue, dizziness,
cough, and dyspnea
CONCLUSION — Filgrastim-sndz (Zarxio) is the fi rst
product to be approved by the FDA as a biosimilar It is
similar to fi lgrastim (Neupogen) in effi cacy and safety,
and it costs less ■
1 FDA Biosimilars Guidances Available at: www.fda.gov/Drugs/ GuidanceComplianceRegulatoryInformation/Guidances/ ucm290967.htm Accessed March 3, 2016.
2 F Sörgel et al Comparability of biosimilar fi lgrastim with origi-nator fi lgrastim: protein characterization, pharmacodynamics, and pharmacokinetics BioDrugs 2015; 29:123.
3 K Blackwell et al Comparison of EP2006, a fi lgrastim biosimilar,
to the reference: a phase III, randomized, double-blind clinical study in the prevention of severe neutropenia in patients with breast cancer receiving myelosuppressive chemotherapy Ann Oncol 2015; 26:1948.
Low-Dose Meloxicam (Vivlodex) for
Osteoarthritis Pain
▶
The FDA has approved Vivlodex (Iroko), a low-dose
formulation of the nonsteroidal anti-inflammatory drug
meloxicam (Mobic, and generics), for management of
osteoarthritis pain According to the manufacturer, the new formulation aligns with stronger FDA warnings about the cardiovascular risks of NSAIDs and the recommendation to use the lowest possible doses of these drugs.1
Pronunciation Key Meloxicam : mel ox' i kam Vivlodex : viv loe' dex
generally the fi rst-line pharmacologic treatment for osteoarthritis pain Full doses of NSAIDs are more effective than full doses of acetaminophen, but NSAIDs have many more adverse effects, especially
in elderly patients Intra-articular injection of a corticosteroid is a reasonable alternative Opioids can
be used as a last resort for treatment of intractable osteoarthritis pain.2
THE NEW FORMULATION — Vivlodex is available as
5- and 10-mg capsules; standard meloxicam tablets
contain 7.5 or 15 mg of the drug Like Zorvolex
(diclofenac)3 and Tivorbex (indomethacin),4 two
other low-dose NSAIDs available from the same
manufacturer, Vivlodex is formulated as capsules
containing submicron particles
Absorption of meloxicam occurs more rapidly with the capsules than with standard tablets In a study comparing the new 10-mg capsules with 15-mg tablets in fasting healthy adults, mean maximum serum concentrations (Cmax) of meloxicam were
Trang 5The Medical Letter ® Vol 58 (1490) March 14, 2016
Table 1 Meloxicam Products
Available Usual Adult
Meloxicam Formulations Dosage Cost 1
generic 7.5, 15 mg tabs 2 7.5-15 mg $2.30
Ingelheim)
1 Approximate WAC for 30 days’ treatment with the lowest usual dosage
WAC = wholesaler acquisition cost or manufacturer’s published price to
wholesalers; WAC represents a published catalogue or list price and may
not represent an actual transactional price Source: AnalySource® Monthly
February 5, 2016 Reprinted with permission by First Databank, Inc All rights
reserved ©2016 www.fdbhealth.com/policies/drug-pricing-policy.
2 Also available as a 7.5 mg/5 mL PO suspension.
3 The 5- and 10-mg strengths cost the same.
similar with the two formulations, but the median
time to reach peak serum concentrations (Tmax) was
shorter with the new formulation (2 vs 4 hours) Mean
systemic meloxicam exposure (AUC) was 33% lower
with the low-dose capsules.5 As with the standard
formulation, taking the new meloxicam capsules
with food decreases the rate but not the extent of
absorption (Tmax delayed by 3 hours, mean Cmax 22%
lower, no signifi cant effect on AUC)
CLINICAL STUDIES — FDA approval of Vivlodex
was based on the results of a randomized,
double-blind trial in 403 patients ≥40 years old
with confirmed hip or knee osteoarthritis who
had experienced significant pain flares after
discontinuation of acetaminophen or an NSAID
Patients were randomized to receive 5- or 10-mg
capsules of meloxicam or placebo once daily for 12
weeks Both the 5- and 10-mg capsules reduced
pain significantly more than placebo and were
similar in efficacy.6
ADVERSE EFFECTS — In the 12-week clinical trial,
only a small percentage of patients reported adverse
effects; diarrhea, nausea, and abdominal discomfort
occurred in 2-3% of patients taking low-dose
meloxicam versus 0-1% of those taking placebo No
serious adverse effects were reported
Dyspepsia and GI ulceration, perforation, and
bleed-ing can occur with all NSAIDs Serious GI complications
may occur without warning High doses, prolonged
use, previous peptic ulcer disease, concomitant use of
systemic corticosteroids or aspirin (even 81 mg/day),
excessive alcohol intake, and advanced age increase
the risk of these complications
All NSAIDs inhibit renal prostaglandins, decrease
renal blood flow, cause fluid retention, and may cause
hypertension and renal failure in some patients, particularly the elderly Diminished renal function
or decreased effective intravascular volume due to diuretic therapy, cirrhosis, or heart failure increases the risk of NSAID-induced renal toxicity
Use of NSAIDs has also been associated with an increased risk of myocardial infarction and stroke, sometimes occurring during the fi rst few weeks of treatment, in patients with and without risk factors for cardiovascular disease NSAIDs frequently cause small elevations of hepatic transaminases; serious hepatotoxicity is rare
PREGNANCY — Use of NSAIDs in the third trimester
of pregnancy can cause premature closure of the fetal ductus arteriosus In animal studies, NSAIDs have not been teratogenic, but they can delay parturition, leading to an increased incidence of stillbirth
DRUG INTERACTIONS — NSAIDs may decrease
the effectiveness of diuretics, beta-blockers, ACE inhibitors, and some other antihypertensive drugs, and may increase the toxicity of lithium and metho-trexate If taken with warfarin, they can increase the INR Concomitant use of NSAIDs with warfarin
or other anticoagulants is generally discouraged Patients taking aspirin for cardiovascular protection should not take NSAIDs regularly (except for celecoxib) because they can interfere with the antiplatelet effect of aspirin
CONCLUSION — Low-dose meloxicam (Vivlodex)
appears to be effective in relieving osteoarthritis pain, but how it compares in effi cacy and safety to standard-dose meloxicam, which costs much less,
is unknown NSAIDs can be dangerous, particularly
in elderly patients Acetaminophen is preferred for
fi rst-line treatment of osteoarthritis pain ■
1 FDA Drug Safety Communication: FDA strengthens warnings that non-aspirin nonsteroidal anti-inflammatory drugs (NSAIDs) can cause heart attacks or strokes July 9, 2015 Available at: www.fda.gov/Drugs/DrugSafety/ucm451800.htm Accessed March 3, 2016.
2 Drugs for osteoarthritis Med Lett Drugs Ther 2014; 56:80.
3 Low-dose diclofenac (Zorvolex) for pain Med Lett Drugs Ther 2014; 56:19.
4 In brief: Low-dose indomethacin (Tivorbex) for pain Med Lett Drugs Ther 2014; 56:64.
5 A Hussaini et al Pharmacokinetic properties of low-dose Solu-Matrix meloxicam in healthy adults Clin Rheumatol 2015 Dec 5 (epub).
6 R Altman et al Effi cacy and safety of low-dose SoluMatrix meloxicam in the treatment of osteoarthritis pain: a 12-week, phase 3 study Curr Med Res Opin 2015; 31:2331.
Trang 6Isavuconazonium Sulfate
(Cresemba) – A New Antifungal
▶
The FDA has approved isavuconazonium sulfate
(Cresemba – Astellas) for intravenous and oral treatment
of invasive aspergillosis and invasive mucormycosis
in adults Isavuconazonium sulfate is a prodrug of
isavuconazole, a broad-spectrum triazole antifungal
Pronunciation Key Isavuconazonium : eye" sa vue koe" na zoe' nee um
Isavuconazole: eye" sa vue kon' a zole
Cresemba : cree sem' bah
STANDARD TREATMENT — Voriconazole (Vfend,
and generics) is the preferred treatment for invasive
aspergillosis Some experts recommend addition
of an echinocandin (see Table 2), but the role of
combination therapy for initial treatment has not been
well established.1 A lipid formulation of amphotericin
B (AmBisome, Abelcet) is generally used in patients
who cannot tolerate voriconazole Patients who do
not respond to monotherapy are usually treated with
an echinocandin in addition to voriconazole or a lipid
formulation of amphotericin B Posaconazole (Noxafi l)
has been used off-label as salvage therapy
Invasive mucormycosis is generally treated with
a lipid formulation of amphotericin B and surgical
debridement Posaconazole has been used off-label
for oral step-down therapy in patients who have
responded to amphotericin B and as salvage therapy
Voriconazole is not effective for treatment of mucormycosis; invasive mucormycosis has occurred with use of voriconazole for prophylaxis or treatment
of other fungal infections.2 Untreated invasive mucormycosis is almost always fatal
MECHANISM OF ACTION — Like other triazole
antifun-gals, isavuconazole inhibits the synthesis of ergosterol,
an essential component of the fungal cell membrane
SPECTRUM OF ACTIVITY — Isavuconazole is a
broad-spectrum triazole antifungal that has in vitro activity against most Candida spp., Trichosporon spp., Aspergillus spp., the Mucorales, Fusarium spp.,
CLINICAL STUDIES — Approval of isavuconazonium sulfate for treatment of invasive aspergillosis was
based on the results of a double-blind trial (SECURE)
in 516 patients with invasive fungal disease caused by
Table 2 Pharmacology of Isavuconazole
Class Triazole antifungal Formulation 186 mg capsules (100 mg isavuconazole);
372 mg single-use vials containing lyophilized powder for reconstitution (200 mg isavuconazole) Route Oral or IV
Metabolism Hepatic via CYP3A4 and 3A5, followed by UGT Bioavailability 98%
Tmax Oral: 2-3 hours Half-life IV : 130 hours Elimination Oral: Urine (<1%)
Table 1 Some Drugs for Treatment of Invasive Aspergillosis
Drug Some Available Formulations Usual Adult Dosage 1 Cost 2
Azoles
Isavuconazonium sulfate – 372 mg single-use vials; 372 mg IV or PO q8h x 6 doses, then $6678.00 3
Cresemba (Astellas) 186 mg caps 372 mg once/d
Posaconazole – Noxafi l4 (Merck) 300 mg/16.7 mL IV soln; 40 mg/mL 300 mg IV q12h x 2 doses, then 14,852.60
PO susp; 100 mg delayed-release tabs 5 300 mg once/d Voriconazole – generic 200 mg single-use vials; 40 mg/mL 6 mg/kg IV q12h x 2 doses, then 4 mg/kg 9570.30
Vfend (Pfi zer) PO susp; 50, 200 mg PO tabs q12h 6 11,696.50
Echinocandins
Anidulafungin – Eraxis4 (Pfi zer) 50, 100 mg single-use vials 200 mg IV on day 1, then 100 mg once/d 5040.00
Caspofungin – Cancidas (Merck) 50, 70 mg single-use vials 70 mg IV on day 1, then 50 mg once/d 7 9455.90
Micafungin – Mycamine4 (Astellas) 50, 100 mg single-use vials 100-150 mg IV once/d 5236.00
Amphotericin B Products
Amphotericin B lipid complex (ABLC) – 100 mg/20 mL single-use vials 5 mg/kg IV once/d 18,130.00
Abelcet (Sigma Tau)
Liposomal amphotericin B (L-AmB) – 50 mg single-use vials 3-5 mg/kg IV once/d 21,373.80
AmBisome (Astellas)
1 Dosage adjustment may be required for hepatic or renal impairment.
2 Approximate WAC for 4 weeks' treatment with the lowest recommended adult maintenance dosage for a 70-kg patient WAC = wholesaler acquisition cost or manufacturer’s published price to wholesalers; WAC represents a published catalogue or list price and may not represent an actual transactional price Source: AnalySource® Monthly February 5, 2016 Reprinted with permission by First Databank, Inc All rights reserved ©2016
www.fdbhealth.com/policies/drug-pricing-policy Cost of admnistration is not included.
3 Cost for IV formulation Cost for 4 weeks' treatment with PO isavuconazonium sulfate is $3920.00.
4 Not FDA-approved for treatment of aspergillosis.
5 Noxafi l delayed-release tablets and oral suspension are not interchangeable.
6 Patients who are responding may be switched to oral voriconazole, but the optimal dosage has not been established.
7 Daily dose may be increased to 70 mg if response is inadequate.
Trang 7The Medical Letter ® Vol 58 (1490) March 14, 2016
Aspergillus spp or other fi lamentous fungi Patients
were randomized to receive isavuconazonium sulfate
or voriconazole for a maximum of 84 days The rate
of all-cause mortality through day 42 was similar with
the two drugs (19% with isavuconazonium vs 20% with
voriconazole).The overall response rates (complete
and partial) at the end of therapy were also similar in
both groups (35% vs 36%).4
A single-arm trial (VITAL) in a subset of 37 previously
treated or treatment-naive patients with proven or
probable invasive mucormycosis found that
all-cause mortality through day 84 was 43.2% with
isavuconazonium sulfate A complete response at the
end of therapy was achieved in 14.3% of patients.5
According to the manufacturer, an unpublished,
double-blind, randomized trial (ACTIVE) in 440 patients with
candidemia and other invasive Candida infections did
not fi nd isavuconazonium sulfate to be noninferior to
caspofungin (Cancidas); the overall response rate at
the end of IV therapy was 60.3% in the isavuconazole
group and 71.1% in the caspofungin group
ADVERSE EFFECTS — Isavuconazonium sulfate is
generally well tolerated The most common adverse
effects of the drug in clinical trials were nausea,
vomiting, diarrhea, headache, elevated hepatic
transaminases, hypokalemia, constipation, dyspnea,
cough, peripheral edema, and back pain Hypotension,
chills, dizziness, paresthesia, and hypoesthesia have
been reported with IV administration
In the invasive aspergillosis clinical trial, patients
treated with isavuconazonium sulfate had lower
incidences of hepatobiliary (9% vs 16%), eye (15% vs
27%), and skin or subcutaneous tissue (33% vs 42%)
adverse effects than those treated with voriconazole
Drug-related adverse effects were reported in 109
patients (42%) receiving isavuconazonium and in 155
(60%) receiving voriconazole.4
Isavuconazole can shorten the QTc interval; the drug
is contraindicated in patients with familial short QT
syndrome
PREGNANCY — Isavuconazonium sulfate is classifi ed
as category C (perinatal mortality in rats and skeletal
abnormalities in rats and rabbits; no adequate studies
in pregnant women) for use during pregnancy
DRUG INTERACTIONS — Isavuconazole is a substrate of
CYP3A4 and 3A5; coadministration with strong CYP3A4
inhibitors or inducers is contraindicated.6 It is also a
moderate inhibitor of CYP3A4 and mild inhibitor of the
drug transporters P-glycoprotein (P-gp), organic cation transporter 2 (OCT2), and breast cancer resistance
protein (BCRP) In vitro, it inhibits CYP2C8, 2C9, 2C19,
and 2D6 and induces CYP3A4, 2B6, 2C8, and 2C9; the clinical signifi cance of these effects is unknown
DOSAGE AND ADMINISTRATION — The recommended dosage of isavuconazonium sulfate for treatment of
invasive aspergillosis or mucormycosis is 372 mg (IV or PO) every 8 hours for 6 doses, followed by 372
mg once daily The injectable formulation should be reconstituted, further diluted in 250 mL of diluent, and administered over ≥1 hour through an in-line
fi lter to prevent an insoluble precipitate from forming
in the tubing or container The capsules should
be swallowed whole and not be chewed, crushed, dissolved, or opened The capsules and the injectable formulation are bioequivalent and can be used interchangeably
CONCLUSION — Isavuconazonium sulfate (Cresemba),
a prodrug of the triazole antifungal isavuconazole, was
noninferior to voriconazole (Vfend, and generics) in
one clinical trial for treatment of invasive aspergillosis, and was less likely than voriconazole to cause hepato-biliary, ophthalmic, and cutaneous adverse effects It also appears to be effective for treatment of invasive mucormycosis; how it compares to amphotericin B
(AmBisome, and others) or posaconazole (Noxafi l) for
this indication remains to be determined ■
1 KA Marr et al Combination antifungal therapy for invasive as-pergillosis: a randomized trial Ann Intern Med 2015; 162:81.
2 Antifungal drugs Treat Guidel Med Lett 2012; 10:61.
3 GR Thompson 3rd and NP Wiederhold Isavuconazole: a com-prehensive review of spectrum of activity of a new triazole My-copathologia 2010; 170:291.
4 JA Maertens et al Isavuconazole versus voriconazole for pri-mary treatment of invasive mould disease caused by Asper-gillus and other fi lamentous fungi (SECURE): a phase 3, ran-domised-controlled, non-inferiority trial Lancet 2016; 387:760.
5 FM Marty et al Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis Lancet Infect Dis 2016 (in press).
6 Inhibitors and inducers of CYP enzymes and P-glycoprotein Med Lett Drugs Ther 2013; 55:e44.
Table 3 Some Advantages of Isavuconazonium Sulfate
vs Voriconazole 1
▶Once-daily dosing
▶IV formulation can be used in patients with renal impairment
▶No dosage adjustment for mild to moderate hepatic impairment
▶Fewer CYP-mediated drug interactions
▶ Predictable pharmacokinetics
▶ Fewer serious adverse effects
▶Active against Mucorales
1 NN Pettit and PL Carver Ann Pharmacother 2015; 49:825; MH Miceli and
CA Kauffman Clin Infect Dis 2015; 61:1558; MA Slavin and KA Thursky Lancet 2016, 387:726.
Trang 8Questions start on next page
ACCREDITATION INFORMATION:
ACCME: The Medical Letter is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians The Medical
Letter designates this enduring material for a maximum of 2 AMA PRA Category 1 Credits ™ Physicians should claim only the credit commensurate with the extent of their participation in the activity This CME activity was planned and produced in accordance with the ACCME Essentials and Policies.
ABIM MOC: Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 2 MOC points in the
American Board of Internal Medicine's (ABIM) Maintenance of Certifi cation (MOC) program Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
AAFP : This enduring material activity, The Medical Letter Continuing Medical Education Program, has been reviewed and is acceptable for up to 52 Prescribed credits by the
American Academy of Family Physicians Term of approval begins January 1, 2016 Term of approval is for one year from this date Each issue is approved for 2 Prescribed credits Credit may be claimed for one year from the date of each issue Physicians should claim only the credit commensurate with the extent of their participation in the activity
ACPE: The Medical Letter is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education This exam is acceptable
for 2.0 hour(s) of knowledge-based continuing education credit (0.2 CEU)
This activity, being ACCME (AMA) approved, is acceptable for Category 2-B credit by the American Osteopathic Association (AOA)
The National Commission on Certifi cation of Physician Assistants (NCCPA) accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME NCCPA also
accepts AAFP Prescribed credits for recertifi cation The Medical Letter is accredited by both ACCME and AAFP.
The American Nurses Credentialing Center (ANCC) and the American Academy of Nurse Practitioners (AANP) accept AMA PRA Category 1 Credit™ from organizations
accredited by the ACCME
Physicians in Canada: Members of The College of Family Physicians of Canada are eligible to receive Mainpro-M1 credits (equivalent to AAFP Prescribed credits) as per our
reciprocal agreement with the American Academy of Family Physicians
MISSION:
The mission of The Medical Letter’s Continuing Medical Education Program is to support the professional development of healthcare providers including physicians, nurse practitioners, pharmacists, and physician assistants by providing independent, unbiased drug information and prescribing recommendations that are free of industry influence The program content includes current information and unbiased reviews of FDA-approved and off-label uses of drugs, their mechanisms of action, clinical trials, dosage and administration, adverse effects, and drug interactions The Medical Letter delivers educational content in the form of self-study material.
The expected outcome of the CME program is to increase the participant’s ability to know, or apply knowledge into practice after assimilating, information presented in
materials contained in The Medical Letter.
The Medical Letter will strive to continually improve the CME program through periodic assessment of the program and activities The Medical Letter aims to be a leader in supporting the professional development of healthcare providers through Core Competencies by providing continuing medical education that is unbiased and free of industry influence The Medical Letter is supported solely by subscription fees and accepts no advertising, grants, or donations.
GOAL:
Through this program, The Medical Letter expects to provide the healthcare community with unbiased, reliable, and timely educational content that they will use to make independent and informed therapeutic choices in their practice.
LEARNING OBJECTIVES:
Activity participants will read and assimilate unbiased reviews of FDA-approved and off-label uses of drugs and other treatment modalities Activity participants will be
able to select and prescribe, or confi rm the appropriateness of the prescribed usage of, the drugs and other therapeutic modalities discussed in The Medical Letter with
specifi c attention to clinical trials, pathophysiology, dosage and administration, drug metabolism and interactions, and patient management Activity participants will make independent and informed therapeutic choices in their practice.
Upon completion of this program, the participant will be able to:
1 Discuss the safety of testosterone replacement therapy
2 Describe how a biosimilar product compares to a reference product and how Zarxio and Neupogen compare to one another.
3 Review the effi cacy and safety of low-dose meloxicam (Vivlodex) for treatment of osteoarthritis pain.
4 Review the effi cacy and safety of isavuconazonium sulfate (Cresemba) for treatment of invasive aspergillosis and invasive mucormycosis.
Privacy and Confi dentiality: The Medical Letter guarantees our fi rm commitment to your privacy We do not sell any of your information Secure server software (SSL) is used
for commerce transactions through VeriSign, Inc No credit card information is stored.
IT Requirements: Windows 7/8/10, Mac OS X+; current versions of Microsoft IE/Edge, Mozilla Firefox, Google Chrome, Safari, or any other compatible Web browser
High-speed connection.
Have any questions? Call us at 800-211-2769 or 914-235-0500 or e-mail us at: custserv@medicalletter.org
medicalletter.org/cme-program
Earn Up To 52 Credits Per Year
Choose CME from The Medical Letter in the format that’s right for you!
▶ Comprehensive Exam – Available online or in print to Medical Letter subscribers, this 130 question exam enables you to earn 26 credits immediately
upon successful completion of the test A score of 70% or greater is required to pass the exam Our comprehensive exams allow you to test at your own pace in the comfort of your home or offi ce Comprehensive exams are offered every January and July enabling you to earn up to 52 credits per year $49/exam.
▶ Free Individual Exams– Free to active subscribers of The Medical Letter Answer 10 questions per issue and submit answers online Earn 2 credits/exam
A score of 70% or greater is required to pass the exam.
▶ Paid Individual Exams – Available to non-subscribers Answer 10 questions per issue and submit answers online Earn 2 credits/exam $12/exam
A score of 70% or greater is required to pass the exam.
Trang 9The Medical Letter ®
Online Continuing Medical Education
DO NOT FAX OR MAIL THIS EXAM
To take CME exams and earn credit, go to:
medicalletter.org/CMEstatus
Issue 1490 Questions
(Correspond to questions #51-60 in Comprehensive Exam #74, available July 2016)
6 Adverse effects of Vivlodex include:
a diarrhea
c abdominal discomfort
d all of the above
7 A 70-year-old woman with osteoarthritis pain controlled with
acetaminophen recently saw an advertisement for Vivlodex and
asks if she should switch to the new formulation You should tell her that:
a acetaminophen is the preferred fi rst-line treatment for management of osteoarthritis pain
b NSAIDs are not as effective as acetaminophen, especially in the elderly
c she should switch to Vivlodex because it causes fewer adverse
effects than acetaminophen
d all of the above
Isavuconazonium Sulfate (Cresemba) – A New Antifungal
8 Invasive mucormycosis is usually treated with surgical debridement and:
b voriconazole plus an echinocandin
c a lipid formulation of amphotericin B
d an echinocandin
9 In the clinical trial for treatment of invasive aspergillosis, isavuconazonium sulfate:
a was signifi cantly more effective than voriconazole in reducing all-cause mortality through day 84 of treatment
b caused less ophthalmic adverse effects than voriconazole
c was associated with overall response rates that were signifi cantly higher than those achieved with voriconazole
d all of the above
10 You are considering treating a 55-year-old woman who has invasive aspergillosis and moderate renal dysfunction with IV voriconazole, but the ID consult suggests IV isavuconazonium sulfate instead Which of the following statements about the two antifungals is true?
a unlike IV voriconazole, IV isavuconazonium sulfate can be used in patients with moderate renal impairment
b isavuconazonium sulfate may have fewer drug interactions
than voriconazole
c following a loading dose, isavuconazonium sulfate is dosed once daily
d all of the above
Safety of Testosterone Replacement Therapy
1 The double-blind, placebo-controlled clinical trials that evaluated
the effi cacy of testosterone replacement therapy in men ≥65 years
old found that the hormone produced the greatest improvement in:
a sexual function
b physical function
c vitality
2 Studies of the association between testosterone replacement
therapy and cardiovascular risk have found:
a an increase in risk
b no signifi cant change in risk
c a decrease in risk
d all of the above
Zarxio – A Filgrastim Biosimilar
3 A biosimilar must:
a not have clinically meaningful differences in safety, purity, or
potency from the reference product
b have the same mechanism of action as the reference product
c have the same route of administration as the reference product
d all of the above
4 Which of the following statements regarding Zarxio is true?
a Zarxio is the second biosimilar fi lgrastim product to be
approved in the US
b in one clinical trial, no signifi cant pharmacokinetic differences
were detected between Zarxio and Neupogen
c in one clinical trial, Zarxio increased the absolute neutrophil
count signifi cantly more than Neupogen
d Zarxio has been associated with more dose-related adverse
effects than Neupogen
Low-Dose Meloxicam (Vivlodex) for Osteoarthritis Pain
5 Which of the following statements regarding the new Vivlodex 10-mg
capsules is true ?
a mean maximum serum concentrations are higher with the new
formulation than with 15-mg meloxicam tablets
b median time to reach peak serum concentrations is shorter
with the new formulation than with 15-mg meloxicam tablets
c the new low-dose formulation is more likely to cause
hepatotoxicity than the standard-dose formulation
d all of the above
ACPE UPN: Per Issue Exam: 0379-0000-16-490-H01-P; Release: March 14, 2016, Expire: March 14, 2017 Comprehensive Exam 74: 0379-0000-16-074-H01-P; Release: July 2016, Expire: July 2017
PRESIDENT: Mark Abramowicz, M.D.; VICE PRESIDENT AND EXECUTIVE EDITOR: Gianna Zuccotti, M.D., M.P.H., F.A.C.P., Harvard Medical School; EDITOR IN CHIEF: Jean-Marie Pflomm, Pharm.D.; ASSOCIATE EDITORS: Susan M Daron, Pharm.D., Amy Faucard, MLS, Corinne Z Morrison, Pharm.D., Michael P Viscusi, Pharm.D.; CONSULTING EDITORS: Brinda M Shah,
Pharm.D., F Peter Swanson, M.D
CONTRIBUTING EDITORS: Carl W Bazil, M.D., Ph.D., Columbia University College of Physicians and Surgeons; Vanessa K Dalton, M.D., M.P.H., University of Michigan Medical School;
Eric J Epstein, M.D., Albert Einstein College of Medicine; Jane P Gagliardi, M.D., M.H.S., F.A.C.P., Duke University School of Medicine; David N Juurlink, BPhm, M.D., Ph.D.,
Sunnybrook Health Sciences Centre; Richard B Kim, M.D., University of Western Ontario; Franco M Muggia, M.D., New York University Medical Center; Sandip K Mukherjee,
M.D., F.A.C.C., Yale School of Medicine; Dan M Roden, M.D., Vanderbilt University School of Medicine; Esperance A.K Schaefer, M.D., M.P.H., Harvard Medical School; F Estelle
R Simons, M.D., University of Manitoba; Neal H Steigbigel, M.D., New York University School of Medicine; Arthur M F Yee, M.D., Ph.D., F.A.C.R., Weill Medical College of Cornell
University
MANAGING EDITOR: Susie Wong; ASSISTANT MANAGING EDITOR: Liz Donohue; EDITORIAL ASSISTANT: Cheryl Brown
EXECUTIVE DIRECTOR OF SALES: Gene Carbona; FULFILLMENT AND SYSTEMS MANAGER: Cristine Romatowski; EXECUTIVE DIRECTOR OF MARKETING AND COMMUNICATIONS: Joanne F Valentino; VICE PRESIDENT AND PUBLISHER: Yosef Wissner-Levy
Founded in 1959 by Arthur Kallet and Harold Aaron, M.D.
Copyright and Disclaimer: The Medical Letter, Inc is an independent nonprofi t organization that provides healthcare professionals with unbiased drug prescribing recommendations The editorial
process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials, and on the opinions of its consultants The Medical Letter, Inc is supported solely by subscription fees and accepts no advertising, grants, or donations No part of the material may be reproduced or transmitted by any process in whole or in part without prior permission in writing The editors do not warrant that all the material in this publication is accurate and complete in every respect The editors shall not be held responsible for any damage resulting from any error, inaccuracy, or omission.
Subscription Services
The Medical Letter, Inc Call: 800-211-2769 or 914-235-0500 To reproduce any portion of this issue, 1 year - $129; 2 years - $232; E-mail: info@medicalletter.org
145 Huguenot St Ste 312 Fax: 914-632-1733 please e-mail your request to: 3 years - $345 $65 per year Call: 800-211-2769 ext 315 New Rochelle, NY 10801-7537 E-mail: custserv@medicalletter.org permissions@medicalletter.org for students, interns, residents, and Special rates available for bulk
Medical